Research Database

When humans enter microgravity many changes to their body take place, such as to the brain and central nervous system which has to adapt to altered sensory information arriving from the eyes, ears, and muscles. This ongoing ESA-sponsored project aims to identify biomarkers for this adaptation via use of advanced MRI (Magnetic Resonance Imaging) brain imaging methods such as Diffusion Tensor Imaging (DTI) and resting state functional MRI (rsfMRI). Identification of neural biomarkers related to sensorimotor adaptation after spaceflight could also lead to improved interventions for humans on Earth, for example after injury or stroke.

‍

This project is developing and testing an artificial intelligence (AI) powered free-flying companion, called CIMON, to support crew and help with mission efficiency during long-term missions. CIMON can fly freely through the ISS to support crew as they perform tasks and can respond to verbal commands. This technology development project is also looking at human machine interactions to build robots and other technologies that are intuitive and easy for humans to use and rely on. The work will help design technologies on Earth that will optimize performance for seamless integration into many sectors, such as manufacturing, aviation, and healthcare.

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Space Diagnostics (Ax-1 CRISPR) tests CRISPR-based genetic identification on the Axiom-1 (Ax-1) private astronaut mission (PAM). CRISPR is a genome editing system that allows its users to detect and manipulate specific DNA and RNA sequences in living cells of diverse species. This technology could provide rapid and accurate detection of pathogens and contaminants on future long-term space missions.

In partnership with Axiom Space, the Cancer in LEO project from the Sanford Stem Cell Institute will study tumor organoids in microgravity with the goal to identify early warning signs of cancer for prediction and prevention of the disease. This project is part of the expanded ISSCOR collaboration between the Sanford Stem Cell Institute, JM Foundation, and Axiom Space, which aims to use microgravity to further understand stem cells, cancer, and aging-related effects in space to develop better prediction of disease and therapeutics for patients on Earth.

The Cancer in LEO-3 investigation builds on research from previous Axiom Space missions that studied cancer growth in space. It aims to validate earlier findings on tumor organoids and explore how a new model of triple negative breast cancer responds to drug challenges in low Earth orbit (LEO). This research is crucial for space missions as it examines the impact of microgravity and radiation in LEO on cancer cell growth compared with growth in a terrestrial environment. The findings could lead to better cancer treatments on Earth by revealing how cancer cells behave in microgravity and identifying new therapeutic targets for metastatic cancers. This project is part of the Integrated Space Stem Cell Orbital Research (ISSCOR) collaboration between the Sanford Stem Cell Institute, JM Foundation, and Axiom Space, which aims to use microgravity to further understand stem cells, cancer, and aging-related effects in space in order to develop better prediction of disease and therapeutics for patients on Earth.